Qilu Hospital of Shandong University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.qiluhospital.com
Derivation of An In-Hospital Cardiac Arrest Prediction Model for Patients in Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 2000
- Registration Number
- NCT04670458
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 128
- Registration Number
- NCT04651049
Neoadjuvant Immunotherapy to ESCC
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Qilu Hospital of Shandong University
- Registration Number
- NCT04625543
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Bevacizumab in Patients With Severe Covid-19
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 588
- Registration Number
- NCT04305106
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 27
- Registration Number
- NCT04275414
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇮🇹Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
2019-nCoV Outbreak and Cardiovascular Diseases
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 12000
- Registration Number
- NCT04255940
- Locations
- 🇨🇳
First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China
🇨🇳The Second Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China
Different β -Blockers in STEMI and Primary PCI
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 1200
- Registration Number
- NCT04221919
Tongxinluo Capsule for Coronary Microvascular Disease
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT04220372
Rhodiola Rosea for Coronary Microvascular Disease
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 114
- Registration Number
- NCT04218916
Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis
Completed
- Conditions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 245
- Registration Number
- NCT04210297
- Locations
- 🇨🇳
Department of Gastroenterology,Qilu Hospital,Shandong University, Jinan, Shandong, China
© Copyright 2024. All Rights Reserved by MedPath